MX2019015071A - Composiciones y metodos para tratar tauopatias. - Google Patents
Composiciones y metodos para tratar tauopatias.Info
- Publication number
- MX2019015071A MX2019015071A MX2019015071A MX2019015071A MX2019015071A MX 2019015071 A MX2019015071 A MX 2019015071A MX 2019015071 A MX2019015071 A MX 2019015071A MX 2019015071 A MX2019015071 A MX 2019015071A MX 2019015071 A MX2019015071 A MX 2019015071A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- methods
- tauopathies
- treating tauopathies
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan regímenes de dosificación y formulaciones de anticuerpos anti-tau humana. Estas formulaciones y regímenes de dosificación son útiles en el tratamiento de tauopatías, tales como la parálisis supranuclear progresiva o la enfermedad de Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2017/037991 WO2018231254A1 (en) | 2017-06-16 | 2017-06-16 | Compositions and methods for treating tauopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019015071A true MX2019015071A (es) | 2020-02-13 |
Family
ID=59388133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015071A MX2019015071A (es) | 2017-06-16 | 2017-06-16 | Composiciones y metodos para tratar tauopatias. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3638694A1 (es) |
JP (2) | JP2020529394A (es) |
KR (1) | KR20200018502A (es) |
CN (1) | CN110770253A (es) |
AU (1) | AU2017418317A1 (es) |
BR (1) | BR112019026298A2 (es) |
CA (1) | CA3064550A1 (es) |
EA (1) | EA202090063A1 (es) |
IL (1) | IL271256A (es) |
MX (1) | MX2019015071A (es) |
WO (1) | WO2018231254A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6674888B2 (ja) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
CN117716034A (zh) | 2021-07-27 | 2024-03-15 | 斯坦德治疗有限公司 | 肽标签和编码该肽标签的核酸 |
KR20230172262A (ko) | 2022-06-15 | 2023-12-22 | 재단법인대구경북과학기술원 | Ptk2 억제제를 유효성분으로 포함하는 타우병증의 예방 또는 치료용 조성물 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
SI2331090T1 (en) * | 2008-09-19 | 2018-04-30 | Pfizer Inc. | Stable liquid antibody formulation |
EA031698B1 (ru) * | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Человеческие анти-тау антитела |
JP5941770B2 (ja) | 2012-06-28 | 2016-06-29 | 株式会社ミマキエンジニアリング | インクジェット記録装置、液体供給装置および記録ヘッドのクリーニング方法 |
BR112015003326A2 (pt) * | 2012-08-16 | 2017-07-04 | Ipierian Inc | métodos de tratamento de uma tauopatia |
EA039554B1 (ru) * | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
BR112016010454A2 (pt) * | 2013-11-27 | 2017-12-05 | Ipierian Inc | métodos para tratar uma taupatia |
WO2016059512A1 (en) * | 2014-10-18 | 2016-04-21 | Pfizer Inc. | Anti-il-7r antibody compositions |
-
2017
- 2017-06-16 CA CA3064550A patent/CA3064550A1/en active Pending
- 2017-06-16 EA EA202090063A patent/EA202090063A1/ru unknown
- 2017-06-16 EP EP17743107.9A patent/EP3638694A1/en not_active Withdrawn
- 2017-06-16 WO PCT/US2017/037991 patent/WO2018231254A1/en active Application Filing
- 2017-06-16 MX MX2019015071A patent/MX2019015071A/es unknown
- 2017-06-16 CN CN201780091913.0A patent/CN110770253A/zh active Pending
- 2017-06-16 AU AU2017418317A patent/AU2017418317A1/en not_active Abandoned
- 2017-06-16 BR BR112019026298-9A patent/BR112019026298A2/pt unknown
- 2017-06-16 JP JP2019569225A patent/JP2020529394A/ja active Pending
- 2017-06-16 KR KR1020197038545A patent/KR20200018502A/ko not_active Application Discontinuation
-
2019
- 2019-12-08 IL IL271256A patent/IL271256A/en unknown
-
2021
- 2021-11-10 JP JP2021182954A patent/JP2022033757A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
KR20200018502A (ko) | 2020-02-19 |
WO2018231254A1 (en) | 2018-12-20 |
CN110770253A (zh) | 2020-02-07 |
AU2017418317A1 (en) | 2019-12-05 |
EA202090063A1 (ru) | 2020-04-03 |
JP2022033757A (ja) | 2022-03-02 |
IL271256A (en) | 2020-01-30 |
JP2020529394A (ja) | 2020-10-08 |
CA3064550A1 (en) | 2018-12-20 |
EP3638694A1 (en) | 2020-04-22 |
BR112019026298A2 (pt) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019015071A (es) | Composiciones y metodos para tratar tauopatias. | |
PH12020500500A1 (en) | Pyrazolopyrimidinone compounds and uses thereof | |
MX2019007587A (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
CY1122265T1 (el) | Αντισωματα εναντι ταυ και χρησεις αυτων | |
MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2020010674A (es) | Agonistas del receptor muscarinico. | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
MX2019005594A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. | |
EA201991029A1 (ru) | Ингибиторы magl | |
EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
MX2021005248A (es) | Anticuerpos contra cd73 activadores de células b. | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
CR20200127A (es) | Anticuerpo anti-pacap | |
WO2018033941A3 (en) | Pharmaceutical compositions of ibrutinib | |
MX2021005245A (es) | Composiciones de oligosacaridos y metodos de uso de las mismas. | |
PH12018502139A1 (en) | Phosphaplatin liquid formulations | |
JOP20190286A1 (ar) | تركيبات وطرق لعلاج اعتلالات تاو | |
PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease |